MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr The ...
The medical device industry landscape is evolving rapidly, driven both by regulatory changes and the quest for innovation. The new European Medical Device Regulation (EU MDR) and its ...